Finerenone for Heart Failure and Kidney Disease Associated With Type 2 Diabetes

,
Drug Topics Journal, Drug Topics November 2021, Volume 165, Issue 11

The FDA has approved finerenone (Kerendia, Bayer) for the treatment of adults with chronic kidney disease (CKD) associated with type 2 diabetes.

The FDA has approved finerenone (Kerendia, Bayer) for the treatment of adults
with chronic kidney disease (CKD) associated with type 2 diabetes.1 Finerenone is a nonsteroidal selective mineralocorticoid receptor (MR) antagonist used to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, endstage
kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure.1,2

Finerenone is activated by aldosterone and cortisol, and it also regulates gene transcription. Finerenone works by blocking MR-mediated sodium reabsorption
and MR overactivation in epithelial and nonepithelial tissues. Finerenone has high potency and selectivity for the MR.